Job Description Our Oncology team is dedicated to delivering breakthrough innovations that extend and improve the lives of cancer patients worldwide. Our team of forward-thinking individuals achieve this through an unwavering commitment to support accessibility to medicine, providing new therapeutic solutions, and collaborating with governments and payers to ensure that people who need medicines have access to them. Our focus is on innovation and launch execution excellence; we translate breakthrough science into innovative medicines that help people with cancer across the globe.
Beyond our consistent and unwavering focus, at this difficult time we are keen to support the healthcare system to overcome the challenges posed by the COVID-19 pandemic. You will work in collaboration with the Director of Medical Affairs for Oncology, the other oncology therapy area heads, the medical operations team, commercial colleagues in the New Product and Early Launch teams and the local and global Value and Implementation team leading on access and reimbursement.
Strategically plan for the implementation of our company’s haematology medicines in associated cancers and utilising the team (and working in partnership with XFTs) to create Medical Action Plans (MAPs) for each key asset. Deliver, through leadership of the team, tactics in the CMAPs to a high standard of medical affairs excellence, and in doing so, seek to administer new capabilities for the team where needed.
Be a key role on Asset Working Groups for the company pipeline in solid tumours and work across the oncology therapy areas to ensure strategic alignment for all new assets. This will include working in partnership with XFTs to co-create Medical Action Plans (MAPs) for each key therapy area.
Represent our Company as the senior leader for our haematology, oncology portfolios and pipeline at clinical or scientific meetings, building strong relationships with top tier stakeholders in healthcare provision, academic research and commissioning.
Translate early CT insight into a robust understanding of patient pathways and clinical practice to prepare the UK business for future launches.
Working in close collaboration with Market Access and Outcomes Research, maintain oversight of UK medical affairs Phase 3b and phase 4 (RWE) projects, with matrix leadership of study operations and budget, delivering an inclusive data generation and publication plan. In partnership with market access and commercial colleagues, deliver effective horizon scanning activities and HTA submissions. Assess directorate team capabilities and operational status to ensure that the team are excelling in meeting UK regulatory and governance frameworks.
Support the implementation of the UK and Ireland medical affairs training programme and contributing to its development. Develop and mentor talent to fulfil their potential, attracting new talent to the organisation and effectively addressing under performance. When appropriate deputise for other medical team members (senior, peers or subordinates).
Medical degree, pharmacy degree or PhD scientist will be considered for this role.
A demonstration of understanding the identification, application and adoption of innovative technologies and processes in the pharmaceutical and/or healthcare delivery environments.
Proven relationship building skills with scientific leaders (either in the pharmaceutical industry or healthcare/academic setting).
Please, no phone calls or emails.
Regular Relocation:
VISA Sponsorship:
Travel Requirements:
Flexible Work Arrangements:
Not Applicable Shift:
Valid Driving License:
Advisory Board Development, Clinical Data Analysis, Clinical Research, Ethical Compliance, Healthcare Education, Hospital Medicine, Key Opinion Leader Management, Management Process, Medical Affairs, Medical Marketing Strategy, Oncology Drug Development, People Leadership, Pharmaceutical Medical Affairs, Publications Planning, Scientific Communications, Scientific Translations, Social Collaboration, Stakeholder Engagement Preferred Skills: